GSK forges ahead with its dynamic COPD and asthma portfolio

For instance, in the UK, US, Canada and Spain, the first treatment was an ICS/LABA, such Seretide or Symbicort, while in Germany it was a bronchodilator.

GSK seeks EU approval for Trelegy in adult asthma patients

GSK’s respiratory business has been hit with the loss of patent protection for its COPD blockbuster Seretide/Advair (fluticasone propionate/salmeterol) – Trelegy is GSK’s answer to the increased competition

GSK considers more divestments to help R&D push

She said it was encouraging that in the year that generic competition really bit hard into sales of GSK’s longstanding respiratory blockbuster Advair/Seretide (fluticasone propionate/salmeterol), the group was

GSK divests travel vaccines to Bavarian Nordic as part of strategic refocus

The revamp at GSK was needed in large part due to generic competition to its blockbuster respiratory treatment Advair.

1 2 3 4 5 6 7 8 9 10 [ Next 5 results ]